RecruitingPhase 4

A Study of Tirzepatide (LY3298176) Compared With Standard of Care in Adult Participants With Obesity and Without Diabetes (SURMOUNT-REAL UK)

United Kingdom3,000 participantsStarted 2025-11-24

Plain-language summary

The purpose of this study is to evaluate tirzepatide within a real-world setting to assess body weight loss and incidence of type 2 diabetes in adults without diabetes who have obesity and at least one weight-related comorbid condition. Participation in the study will last about 260 weeks.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Have a body mass index ≥30 and ≤34.9 kilogram per square meter (kg/m2) * Have an increased waist to height ratio (defined by \>0.5) * Have at least one weight related comorbid condition * Have had at least one attempt to lose weight with lifestyle intervention (diet and physical activity) Exclusion Criteria: * Have type 1 diabetes, type 2 diabetes, or any other types of diabetes * Have had a change in body weight of greater than 5 kilograms (11 pounds) within 90 days prior to screening

What they're measuring

Percent Change from Baseline in Body Weight

Timeframe: Baseline, 24 months

Trial details

NCT IDNCT07247084

SponsorEli Lilly and Company

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2029-07

Contact for this trial

Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or

317-615-4559 LillyTrials@Lilly.com

View on ClinicalTrials.gov More Obesity trials